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Abstract
Background: Epidemiological studies and cardiovascular prevention trials have shown that low-dose aspirin can
reduce colorectal cancer (CRC) incidence and mortality, including inhibition of distant metastases. Metformin has
also been associated with decreased colon adenoma recurrence in clinical trials and lower CRC incidence and
mortality in epidemiological studies in diabetics. While both drugs have been tested as single agents, their
combination has not been tested in cancer prevention trials.
Methods/design: This is a randomized, placebo-controlled, double-blind, 2 × 2 biomarker trial of aspirin and
metformin to test the activity of either agent alone and the potential synergism of their combination on a set of
surrogate biomarkers of colorectal carcinogenesis. After surgery, 160 patients with stage I-III CRC are randomly
assigned in a four-arm trial to either aspirin (100 mg day), metformin (850 mg bis in die), their combination, or
placebo for one year. The primary endpoint biomarker is the change of IHC expression of nuclear factor kappa-B
(NFκB) in the unaffected mucosa of proximal and distal colon obtained by multiple biopsies in two paired
colonoscopies one year apart. Additional biomarkers will include: 1) the measurement of circulating IL-6, CRP and
VEGF; 2) the IHC expression of tissue pS6K, p53, beta-catenin, PI3K; 3) the associations of genetic markers with
treatment response as assessed by next generation sequencing of primary tumors; 4) the genomic profile of
candidate genes, pathways, and overall genomic patterns in tissue biopsies by genome wide gene expression
arrays; and 5) the evaluation of adenoma occurrence at 1 year.
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Discussion: A favorable biomarker modulation by aspirin and metformin may provide important clues for a
subsequent phase III adjuvant trial aimed at preventing second primary cancer, delaying recurrence and improving
prognosis in patients with CRC.
Trial registration: EudraCT Number: 2015–004824-77; ClinicalTrial.gov Identifier: NCT03047837. Registered on
February 1, 2017.
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Background
Colorectal cancer is the second most frequent cause of
cancer-related death in Western Europe. Despite advances
in surgical and adjuvant treatment over the past two de-
cades, survival remains poor, with a 5-year survival well
below 60% in patients undergoing resection with curative
intent [1, 2]. Recent results of EUROCARE-5, a retrospect-
ive observational study based on data from 107 cancer
registries for more than 10 million patients with cancer di-
agnosed up to 2007 and followed up to 2008, provide clear
evidence that effective treatment of colorectal cancer
(CRC) is currently an unmet medical need in Europe [3].
For CRC, the European mean age-standardized 5-year sur-
vival was 57.0% (95%CI 56.8–57.3), with negligible differ-
ences between the sexes. Given that the current standard
adjuvant therapy of CRC has not improved for the last 10
years, there is a clear need for a preventive intervention
aimed at assessing the effectiveness of innovative and low
toxicity interventions designed to prevent tumor recurrence
and/or second cancer. Aspirin and metformin, two com-
mon, safe and inexpensive drugs with a broad spectrum of
preventive effects on several target systems, have recently
shown a preventive potential (both in primary and tertiary
prevention) against several cancers, including CRC.
Meta-analyses of randomized clinical trials for the pre-
vention of vascular disease indicate that daily aspirin
(75 mg upwards) reduces cancer incidence and mortality.
These effects are particularly evident for CRC where a
30–40% reduction in incidence and mortality have been
observed [4, 5]. The risk of developing distant metastasis
was also reduced in aspirin users (HR 0.45; 95% CI
0.28–0.72), with a further lowering risk for CRC patients
(HR 0.26, 95 %CI, 0.11–0.57) [6]. Benefits were already
evident as early as after 2 years from treatment initiation.
These shorter-term effects of aspirin on distant metastasis
are consistent with experimental evidence in animals due to
platelets involvement in blood-borne metastases [7]. Data
obtained from the Nurses’ Health Study and the Health Pro-
fessionals Follow-up Study also showed that regular use of
aspirin after diagnosis was associated with longer survival
among patients with mutated-PIK3CA CRC [8], and our re-
cent meta-analysis suggests that the benefit of post-diagnosis
aspirin treatment on overall mortality in CRC may be more
marked in PIK3CA mutated tumours [9].
The recognition that the hyper-insulinemic state associ-
ated with metabolic syndrome or type II diabetes mellitus
is linked with increased cancer risk has led to intensified
interest in the potential of various anti-diabetic drugs to
prevent cancer [10]. Higher body mass index (BMI) is
strongly associated with CRC risk and with high levels of
insulin and insulin growth factors (IGFs) [11].
As a first-line diabetic agent, metformin has been asso-
ciated with reduced cancer incidence and mortality in
diabetic patients[12] and CRC patients specifically [13].
In a clinical trial of individuals not taking non-steroidal
anti-inflammatory drugs (NSAIDs), a 250mg/day dose
of metformin was sufficient to decrease aberrant crypt
foci, suggesting that a lower dose of metformin could
play a role in colon cancer prevention in this population
[14]. In a recent randomized [15], placebo-controlled,
multicenter trial, in patients who underwent resection of
single or multiple colorectal adenoma polyps, a low-dose
of metformin (250 mg/day) administered for 1 year sig-
nificantly reduced the risk of total polyps (RR = 0.67;
95% CI: 0.47–0.97) and adenomas (RR = 0.60, 0.39–0.92)
compared with placebo.
Several preclinical studies have reported that aspirin and
metformin reduced cell proliferation, induced apoptosis, and
caused cell cycle arrest targeting common signaling path-
ways. Both drugs are activators of AMP kinase (AMPK),
leading to down-regulation of the mTOR pathway that is
crucial to tumor cell metabolism [16, 17]. Moreover, their
combination has a striking additive effect on AMPK activa-
tion and mTOR inhibition, with increased autophagy in
CRC cell lines [18, 19]. The two agents have also been shown
to act synergistically at low concentrations (1–5mmol/L) to
inhibit pancreatic cancer cell line growth and increase cell
death by inhibiting the phosphorylation of mTOR, S6K,
JAK2, and STAT3 [20]. It has been reported that metformin
activated AMPK and inhibited mTOR by suppressing NF-κB
and CREB [21]. Besides, aspirin has shown a pro-apoptotic
activity through modulation of the NFκB pathway, which
was particularly evident in CRC cells [22]. NF-kB is not a val-
idated clinical endpoint for CRC but plays a pivotal role in
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tumor initiation and progression and is known to be consti-
tutively activated in CRC [23].
To date, no clinical trial has ever tested the combination
of aspirin and metformin. Our clinical trial aims to assess
a potential synergistic interaction on a set of biomarkers
associated with colon carcinogenesis, some of which may
serve as predictive biomarkers of drug effects. This will be
tested on biomarkers expressed in the unaffected colonic
mucosa, which are associated with the adenoma carcin-
oma sequence. The cancerization field effect represents a
pre-malignant stage in progression to many cancers, so
the use of the patients’ unaffected mucosa for the evalu-
ation of biomarkers in patients with prior CRC may pro-
vide an indicator of preventive activity/efficacy [24, 25].
Methods/design
Objectives
Primary objective
The primary objective is to test the synergistic effect of
the combined treatment with low dose aspirin plus met-
formin given for one year to reduce the ICH expression
of NFκB in unaffected colonic tissue in patients with re-
moved CRC. The primary endpoint is the change, de-
fined as the difference between post- and pre-treatment
levels, in NFκB expression in the unaffected mucosa of
proximal and distal colon obtained by multiple biopsies
in two paired colonoscopies one year apart.
Secondary objectives
Secondary objectives are:
1. To test the effect of treatment with aspirin and metfor-
min, in combination and independently, on the following
secondary endpoints:
 The change in immunohistochemistry (IHC)
expression levels of pS6K, p53, β-catenin, PI3K
(from unaffected colon biopsy specimens);
 The change in the circulating biomarkers IL-6, CRP,
VEGF, and HOMA index [homeostasis model
assessment [fasting blood glucose (mmol/L)*insulin
(mU/L) / 22.5];
 The gene expression levels of candidate genes
(PTGS1-COX1, PTGS2-COX2, VEGF, TNFα, EGFR,
NFκB), pathways (mTOR signaling - KEGG04150;
NFκB signaling - KEGG04064; VEGF signaling –
04370; FoxO signaling KEGG04068; Regulation of
autophagy - KEGG04140), and genome-wide expres-
sion profile in unaffected colon biopsy tissue.
2. To define the blood and tissue drug levels of met-
formin, considering the genetic variability of specific
membrane-bound drug transporters which may affect
metformin pharmacokinetics and tissue distribution.
3. To genetically characterize the primary CRC using
next generation sequencing (NGS) on a panel compris-
ing 180 amplicons of 30 genes (including KRAS, BRAF,
NRAS, APC, PIK3CA, TP53, CTNNB1 and EGFR) and
determine their association with treatment response.
4. To study the treatment tolerability comparing inci-
dence and grade of toxicities (safety endpoint) among
arms (categorized using the Common Terminology
Criteria for Adverse Events, CTC-AE version 4.03).
5. To study the serum concentrations of thromboxane
B2 (TxB2) as a biomarker of treatment adherence to be
correlated with biomarker modulation and toxicity.
6. To evaluate the effect of treatment on psychological
variables (distress, anxiety, and depression) and cancer-
related fatigue and to explore their interactions with
treatment on the endpoint biomarkers.
7. To evaluate the occurrence of adenoma (low, inter-
mediate and/or high grade intraepithelial neoplasia) at base-
line and 12months after randomization according to the
Vienna classification of gastrointestinal epithelial neoplasia.
In a patient subset additional analyses are planned
with the following secondary objectives:
 Metabolomic analysis: the change of low molecular
weight compounds in serum samples (up to 53
analytes) to obtain a signature of response to therapy.
 The 12month change of microbial composition by
sequencing of the 16S rRNA gene of the colorectal
microbiota by NGS analysis in colonic tissue and feces.
 The 12 months change in auto-antibody composi-
tions in serum samples (ASMA, AMA, APCA, ANA,
ANCA, ASCA, ENA/dsDNA, and TPO) by ELISA
and immunoblotting assays.
 To evaluate the interactions between treatment and
physical activity, life style and food habits on the
endpoint biomarkers.
Moreover, an exploratory objective of the study is to
discover analytically (using STEPP statistical analysis, see
statistical methods) putative metabolic/molecular and
psychological patterns able to define subgroups of pa-
tients in which treatment could be more (or less) active
(personalized treatment).
Study design
The study is a randomized phase II, double-blind,
double-dummy, placebo-controlled, multicenter, 2 × 2
factorial design clinical trial in cancer patients, aged ≥
18 ≤ 80 years, with completely resected stage I-III primary
CRC within 24months prior to randomization, regardless
of (neo-)adjuvant chemotherapy. A total of 160 patients
will be accrued, during an 18-month enrollment period.
All patients will participate in up to 28 days screening,
during which they will be assessed for eligibility. After
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screening and verification of eligibility criteria, eligible pa-
tients who provide informed consent will be randomly al-
located with a ratio of 1:1:1:1 to one of the following 4
arms (40 patients per arm) and treated for one year:
Arm A: placebo aspirin (1 tablet daily, quaque die, qd) +
placebo metformin (1 tablet bis in die, bid).
Arm B: placebo aspirin (1 tablet qd) + active metformin
(850mg metformin, 1 tablet bid).
Arm C: active aspirin (100mg acetylsalicylic acid, 1
tablet qd) + placebo metformin (1 tablet bid).
Arm D: active aspirin (100 mg, 1 tablet qd) + active
metformin (850 mg, 1 tablet bid).
Figure 1 illustrates the overall study design. Table 1
presents the inclusion/exclusion criteria.
Study procedures
An overview of “Visit schedule and assessments” is pro-
vided in Table 2.
Screening visit/ registration
Potential patients will be invited for a detailed discussion of
the protocol with the Principal Investigator or a delegate.
After obtaining written informed consent, patients will
undergo within 28 days prior to first study drug administra-
tion (day − 28 to day 1) the following screening procedures:
inclusion and exclusion criteria check (Table 1); review of
medication history and therapy of current CRC; physical
examination: height, weight, measurement of vital signs (in-
cluding blood pressure, heart rate, and body temperature),
and registration of ECOG Performance Status; haematol-
ogy, biochemistry, and coagulation profile, and a pregnancy
test for women with childbearing potential according to
local/national guidelines.
Baseline
At baseline, all enrolled patients will undergo colonoscopy
with biopsies and blood samples for biomarker assessment.
At baseline and after 12months, only the Italian patients
will collect feces before colon cleansing in preparation for
colonoscopy. Before colonoscopy, patients will complete
validated questionnaires to evaluate cancer related fatigue
(FACIT-F), anxiety and depression (HADS), cancer-related
distress (Distress), physical activity (IPAQ), and eating
habits (EPIC- FFQ short version for the Italian patients
only). The baseline colonoscopy will be performed between
3 and 24months after surgery as per standard clinical prac-
tice. The occurrence of adenoma (low, intermediate, and/or
high grade intraepithelial neoplasia) will be determined
using standard clinical practice. In patients treated with ad-
juvant chemotherapy, baseline colonoscopy will be per-
formed at least 3months after chemotherapy completion.
Pinch biopsies are not standard of care in unremarkable
areas of the colonic tissue but have not been associated
with increased risk of bleeding or perforation [26, 27]. At
the baseline clinic visit, patients will be instructed on the
importance of drug compliance and will be provided with
an investigational drug kit and a pill diary to be completed
daily, signed, and dated. The first drug administration
should occur the day after colonoscopy/baseline visit. Con-
comitant medication and any adverse event (AE) occurring
from the screening period will be registered.
4 and 8month visits
A clinical visit will be performed every 4months (± 2weeks)
to register vital signs, umbilical waist circumference (UWC),
ECOG performance status, adverse events, drug compliance,
concomitant medication and smoking habits. Blood samples
Fig. 1 Overall Study Design
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will be collected for safety tests, metformin and TXB2 quan-
tification in plasma and serum. At each 4months visit pa-
tients will be provided with a new investigational drug kit
and compliance evaluation via pill count will be done.
12-month visit
One year (± 2 weeks) after day 1, patients will return to
the clinic to repeat colonoscopy and biopsies as well as
blood sample collection for safety tests and biomarker as-
sessments. Before colonoscopy, the following procedures
will be done: measurement of vital signs; registration of
ECOG performance status; update of concomitant medi-
cations and procedures; collection of questionnaires; side
effect and compliance evaluation via pill count; and for
the Italian subset of patient’s feces collection.
End of study visit
The end of study visit will be performed 30 days after last
study agent dose per protocol (Visit 12months + 30 days).
For patients who will end treatment early, a visit will be
performed 30 days after the last intake of study agent. All
patients will undergo a physical examination (weight,
UWC, and measurement of vital signs), registration of
ECOG performance status and side effect evaluation.
Colonoscopy and pinch biopsies clinical procedures
All enrolled patients will undergo colonoscopy with biop-
sies at baseline and after 12months of treatment. Colonic
biopsies will be collected both in the right and the left
colon (6 specimens per site) in order to study the pharma-
cokinetic and pharmacodynamic properties of the drugs
and to verify if there is a different preventive effect in the
right versus left colon according to a different anatomic
gradient of mutational status [28]. In patients who re-
ceived right colectomy, 6 biopsies will be taken at the level
of the cul de sac and 6 biopsies 2 cm above the third
Houston valve. In patients operated for a left-side CRC, 6
biopsies will be collected near the ileo-cecal valve and 6
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
•Patients aged > 18 and≤ 80 years.
•Patients with completely resected stage I, II, or III primary CRC within
24months prior to randomization, regardless of (neo-)adjuvant
chemotherapy. Patients with pT1 CRC treated with
endoscopic polypectomy.
•Adjuvant chemotherapy and (neo-)adjuvant radiotherapy terminated
at least 3 months before randomization.
•ECOG performance status ≤1.
•Platelets ≥100 × 10^9/L;
•Creatinine clearance estimated with the Cockcroft - Gault formula
≥60 mL/min. Patients with Gault formula ≥30–59≤ml/min are eligible
but they will receive a single (evening) tablet of metformin, 850 mg.
•AST and ALT ≤2.5 times upper limit of normal (ULN).
•Females of childbearing potential/males with partners of childbearing
potential participating in the study are to use effective methods of birth
control during study participation. Female participants must provide a
pregnancy test, according to local/national guidelines.
•Able to understand and sign an informed consent (or have a legal
representative who is able and willing to do so).
•Patients who are not able to undergo colonoscopy.
•Patients who are allergic or intolerant to ibuprofen or naproxen, or who
have metformin, or aspirin, or salicylate intolerance or more generalized
drug intolerance to NSAIDs.
•Any serious medical condition, laboratory abnormality, or psychiatric
illness that would prevent the patient from signing or participating in the
study and/or comply with study procedures.
•Chronic treatment with aspirin or other NSAIDs or metformin or patients
who are on current long-term treatment (≥ 4 consecutive weeks) with
aspirin, NSAID, COX − 2 inhibitors, or metformin.
•Diabetic patients on drug treatment.
•Anticoagulant therapy (e.g. dicumarol, heparin, fondaparinux, apixaban,
dabigatran etexilate, rivaroxaban) or active current treatment with
antiplatelet agents (e.g. off-study aspirin, clopidogrel, prasugrel, ticagrelor,
or ticlopidine).
•Any other invasive malignancies (with the exclusion of basal cell
carcinoma or cutaneous squamous cell carcinoma) diagnosed during
the last 5 years before randomization. Past history of any other invasive
CRC than the one the patient is currently being treated for.
•Alcohol or drug abuse.
•Prior history of gastro-intestinal bleeding or hemorrhagic diathesis
(e.g. hemophilia).
•Erosive-ulcerative lesions in the gastrointestinal tract.
•History of erosive gastro-esophageal reflux disease (GERD) or active
erosive GERD on gastroscopy.
•Concomitant corticosteroid treatment.
•Known deficiency of glucose-6-phosphate dehydrogenase (G6PD).
•Treatment with another investigational drug < 28 days prior to study entry.
•Concurrent participation in a clinical trial with the same endpoints.
•History of hemorrhagic stroke.
•Lynch Syndrome.
•Crohn’s disease or ulcerative colitis.
•Pregnant or lactating females.
•History of lactic acidosis.
•Liver dysfunction including chronic active hepatitis and cirrhosis
not compensated.
•History of vitamin B12 deficiency or megaloblastic anemia.
•Uncontrolled coronary syndrome or symptomatic congestive heart
failure (e.g. Class III or IV New York Heart Association’s
Functional Classification).
•Inability or unwillingness to swallow tablets.
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biopsies 2 cm above the third Houston valve or 2 cm above
the anastomosis in patients operated for rectal cancer.
Trial organization
The ASAMET trial is designed and coordinated by the
Medical Oncology Unit at E.O. Ospedali Galliera, Genoa,
Italy. Statistical analysis of the main clinical trial will be per-
formed at the Clinical trial office of the coordinating center
(Galliera). The Austrian Breast and Colorectal Cancer
Study Group is responsible for the Clinical Data Manage-
ment System of the entire trial (including programming of
the clinical database, i.e., electronic Case Report Forms for
web-based data entry) and for the randomization system.
The enrollment of this multicenter project will be
conducted at the following sites: Galliera Hospital, Italy;
University Medical Centre Ljubljana, Slovenia; Medical
University of Vienna, Medical University Innsbruck and
Hospital Wels-Grieskirchen (Klinikum Wels-Grieskirchen
GmbH), Austria. The immunohistochemical assessments
will be performed by the Institute of Pathology, University
Medical Center Mainz. The pharmacokinetic assays and
the circulating and genomic biomarkers assessments will
be performed at the Department of Clinical Pharmacology
and Pharmacoepidemiology and the Statistical Genetics
Group Institute of Medical Biometry and Informatics,
University Hospital Heidelberg, Germany, respectively.
Randomization and blinding
The assignment of patients to treatment arms is performed
using the centralized randomization system ‘Randomizer®’,
which is maintained by the Institute of Medical Statistics
and Informatics at the Medical University of Vienna. The
Randomizer provides a self-serve, easy-to-use, secure, and
24 h-a-day randomization service for multi-center clinical
trials that runs exclusively on the Internet. Randomization
is performed using a permuted randomized blocks design.
Stratification factors are the center of enrollment and
(neo-)adjuvant chemotherapy (no versus yes). The confirm-
ation of randomization is automatically generated by the
system and sent back to the specified recipient via e-mail.
Details for the randomization procedure are provided in a
manual stored in the Trial Master File/Site Study File of
Table 2 Visit schedule and assessments
Assessments Treatment Period
Screening1 Randomization Baseline 4 Months 8 Months 12 Months End of study visit
Informed consent X
Inclusion/exclusion criteria X
Relevant medical history X
Prior medication/therapy of current CRC X
Physical exam, vital signs and ECOG performance status X X X X X X
Hematology, biochemistry, and coagulation profile X2 X2 X2 X2 X2
Randomization X
Blood collection for biological assessment X X
Blood collection for TxB2/metformin quantification3 X X X X
Feces collection4 X X
Questionnaires (FACIT, HADS, Distress, IPAQ, and EPIC [4]) X X
Colonoscopy and biopsies X5 X5
Adverse events X6 X X X X X
Concomitant medication X X X X
Study treatment supply X X X
Compliance (via pill count) X X X
1. Within 28 days after day 1
2. Complete blood count (WBC, white blood cell differential count, RBC, Hb, Ht, MCV, MCH, MCHC, RDW, PLT, and MPV), alanine aminotransferase (ALT), aspartate
aminotransferase (AST), creatinine, fasting glucose, triglycerides, and cholesterol. Coagulation profile (coag) includes: (International Normalized Ratio) INR,
Activated Partial Thromboplastin Time (APTT), prothrombin time (PT), and fibrinogen. At baseline, hematology, biochemistry, and coagulation profile are not
needed if the screening visit is performed within 7 days prior to the baseline visit.
3. TxB2/metformin quantification will be performed at the end of the study
4. Only for Italian patients
5. During the colonoscopies at baseline and at 12months, the occurrence of adenoma (low, intermediate, and/or high grade intraepithelial neoplasia) as well as the
histopathological subtype (e.g. tubular, villous, tubulovillous, sessile serrated, traditional serrated, or hyperplastic) will be determined upon routine histopathological
analysis according to local practice (i.e. according to the Vienna classification of gastrointestinal epithelial neoplasia). If at least two adenomas with different grading
exist, the highest grade will be considered, e.g. occurrence of two intermediate-grade and one high-grade adenoma would result in a categorization as high-grade
6. Adverse event (trAE) reporting will begin on the date the patient provides informed consent to participate in the study (documentation in the eCRF will only be
done for randomized patients) and end 30 days after last study drug dose or at the end-of-study visit, which ever occurs first. During the screening phase, only
AEs deemed to be serious (SAEs) and related to protocol and not routinely performed procedures have to be reported
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each enrolling center. The study staff will dispense the
treatment to the patients, during the baseline visit, based
on the assigned randomization number/kit code. None of
the staff interacting with patients will know the link be-
tween kit code and actual treatment. The code that identi-
fies the treatment will be kept by the statistician at the
central data management site.
Unblinding is not expected to occur until all patients
complete their intervention and data entry is complete. If
deemed medically necessary, study treatments may be un-
blinded by the Principal Investigator in consultation with the
Project Coordinator in the event of a serious adverse event.
Safety profile and monitoring
In this study, all AE encountered during the clinical study
will be reported on case report forms. In case of a serious
adverse event (SAE), the investigator has a legal require-
ment to inform the coordinating center office within 24 h
via the SAE report form. The coordinating center is respon-
sible for the management of the safety reporting according
to European regulation and guidelines. All observed AEs
will be evaluated and graded according to the CTCAE, ver-
sion 4.03. All observed SAEs will be discussed by an inde-
pendent data safety monitoring board.
Patients will be asked to maintain the full dose through-
out the treatment period. However, in case of grade 2 or
higher toxicity, dose modification as per protocol will be
applied and recorded. The dose will be changed according
to the potential relationship to study drugs.
The incidence of metformin-related diarrhea in pa-
tients with CRC after surgery is unknown and will there-
fore be closely monitored. Possible dose modifications in
the initial weeks of treatment may be envisioned if the
incidence of this AE turns out to be high.
A Data and Safety Monitoring Board (DSMB) will re-
view the progress of the clinical trial and monitor par-
ticipant safety. During their scheduled meetings, the
DSMB will review clinical data, and meeting reports or
recommendations will be forwarded to the PIs.
Sample size and power consideration
The sample size is 40 patients per arm, resulting in a total of
160 patients to be enrolled. Results from our previous clinical
trial [29] showed a mean change (standard deviation, SD) of
the difference between post- and pre- treatment levels in
NFκB equal to + 5% (25%) in the placebo arm versus −
13.5% (25%) in the active (allopurinol) arm. This is equivalent
to a− 18.5% absolute difference between treatment arms.
Table 3 illustrates the hypothesized treatment effects on
NFκB change and relative power in each arm, assuming a
normal distribution of the change in NFκB with a
mean = 5% in the placebo arm, an equal SD = 25% in all
arms, and a two sided alpha error = 5%. The primary ana-
lysis will have 80% power to detect a synergistic effect in
the combination arm, which is equal to 3-fold single drug
effects (i.e.: + 5% arm A vs. -55% arm D). The hypothesis
of a striking synergistic effect is based on recent preclinical
data of the combination of aspirin and metformin on CRC
cell lines as well as pancreatic cancer cell lines [19, 20]. The
secondary analyses relative to the main drug effects will
have 90% power to detect a difference on the change equal
to − 18.5%, compared to the placebo arm (i.e.: + 5% arm A
vs. − 13.5% arm B or C), which is the same effect we
detected in a previous trial with allopurinol [29]. The
calculation takes into account a 10% drop-out rate: there-
fore the minimum number of patients to be analyzed is
set to n = 144 (36 per arm). The sample size estimate, and
relative power calculation, was performed using a simula-
tion approach (10.000 trials) using R-project software.
Statistical analysis
The synergistic effect of aspirin + metformin vs. placebo on
the primary endpoint will be assessed using a two-way ana-
lysis of covariance (ANCOVA). A multivariate linear regres-
sion model will be adopted to study the change in the
primary endpoint as a function of treatment and potential
confounders or effect modifiers, and to adjust for imbalances
between treatment arms. The interaction parameter between
treatment arms will be primarily estimated and tested.
Secondary analyses
Two-way ANCOVA and multivariate linear modeling will
also be applied to estimate and test the main effects of as-
pirin and metformin alone and to test the association be-
tween the secondary endpoints and treatment, adjusting for
demographical and clinical factors. First and second level
interaction effects between treatment and covariates (other
biomarkers or demographics/clinical characteristics such as
BMI and HOMA index) on primary and secondary end-
points will be tested in each model. The change of highest
grade adenoma at baseline to highest grade adenoma after 1
year after randomization (no adenoma vs low/intermediate
vs high grade adenoma) will be compared between the as-
pirin + metformin and placebo arms using a Wilcoxon test.
Gene expression levels will be analyzed using log-trans-
formed normalized gene expression levels according to the
following three-tiered approach to investigate:
Table 3 Hypothesized effect after 1 year of treatment on the
primary endpoint
Treatment arm N NFκB % change 1-β (power)
Arm A (placebo) 40 + 5% –
Arm B (metformin) 40 −13.5% 90%
Arm C (aspirin) 40 -13.5% 90%
Arm D
(aspirin+metformin)
40 −55%
(~ 3.0-fold the main effects)
80%
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a) Candidate genes (e.g. PTGS1 (COX1), PTGS2
(COX2), VEGF, TNFα, EGFR, NFκB);
b) Candidate pathways (e.g. mTOR signaling -
KEGG04150, NFκB signaling - KEGG04064, VEGF
signaling - KEGG04370, FoxO signaling - KEGG04068,
Regulation of autophagy - KEGG04140);
c) Genome-wide expression profiles.
Comparisons of changes of candidate genetic markers be-
tween arms will be assessed using linear regression from
NGS data. To assess the pathway effect as part of the genetic
analyses, gene-set enrichment analysis and global tests will
be used. Models will be adjusted by age and gender. The ef-
fect size will be expressed using fold change values. We will
visualize the possible subgroups with heat maps using un-
supervised clustering. We will use Ingenuity Pathway Ana-
lysis (IPA) and Cytoscape for visualizing the results of the
pathway analysis. The statistical analyses of genetic data (ex-
pression and genetic characterization of adenocarcinoma
using NGS) will be performed in collaboration between the
Italian and the German PIs. Statistical analyses will be per-
formed using STATA, SAS, R-project, and Bioconductor
software packages.
Exploratory analyses
Subpopulation Treatment-Effect Pattern Plot methodology
(STEPP) [30] will be employed to display graphically the
treatment effect along the continuous scale of the effect
modifiers, using overlapping patient subgroups, to define
subgroups of patients with different drug response.
Discussion
Despite considerable advances in our understanding of can-
cer biology, early diagnosis of CRC remains elusive. Based
on the adenoma-carcinoma sequence, cancer develops
through the progressive accumulation of mutations in key
genes that regulate cell growth. This project is the first clin-
ical trial testing the combination of aspirin and metformin
that will provide us with considerable insight into the biol-
ogy of at-risk colonic mucosa adjacent to the removed neo-
plastic lesion. This field cancerization study could enable
identification of the earliest steps in CRC recurrence and
better understand the molecular targets of the chemopre-
ventive effect of aspirin and metformin and their potentially
synergistic effect in CRC patients. Moreover, the multidis-
ciplinary approach of this study will allow communication
with other researchers and departments to share ideas and
foster collaborations. The trial was activated in April 2017.
As of February 28, 2018, 36 patients were screened and 33
patients recruited. Recruitment is expected to end by sum-
mer of 2018 and participant treatment by summer 2019.
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